SCHEDULE: Major Shareholder Cuts VOR BIOPHARMA Stake to 18.6%

Reprogrammed Interchange LLC and Reid Hoffman significantly reduced their beneficial ownership in VOR BIOPHARMA INC. through open market sales, now holding 18.6% of common stock.

Summary

• Reprogrammed Interchange LLC and Reid Hoffman, collectively the Reporting Persons, filed Amendment No. 7 to their Schedule 13D for VOR BIOPHARMA INC.
• The filing reports open market sales of VOR BIOPHARMA INC. common stock by Reprogrammed Interchange LLC between October 10, 2025, and October 14, 2025.
• These sales decreased the Reporting Persons' beneficial ownership by more than one percent of the outstanding shares.
• Specific sales include 40,983 shares on October 10, 2025, at a weighted average per share sale price of $30.9673; 22,006 shares on October 13, 2025, at $32.436; and 33,668 shares on October 14, 2025, at $30.3192.
• The Reporting Persons now beneficially own 1,278,118 shares, representing 18.6% of the common stock.
• The filing also details numerous sales transactions by Reprogrammed Interchange LLC during the past 60 days, from August 25, 2025, through October 9, 2025, with prices ranging from approximately $30.80 to $42.33 per share, adjusted for a 1-for-20 reverse stock split effected on September 18, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the significant and continuous selling activity by a major shareholder, indicating a potential loss of confidence or a strategic exit, which typically exerts downward pressure on the stock price.

Negatives

• A significant shareholder, Reprogrammed Interchange LLC, has substantially reduced its stake in VOR BIOPHARMA INC. through continuous open market sales.
• The beneficial ownership of the Reporting Persons (Reprogrammed Interchange LLC and Reid Hoffman) decreased by more than one percent of the outstanding shares, signaling a notable divestment.
• The consistent selling activity over the past 60 days by a major investor could indicate a lack of confidence in the company's near-term prospects or a strategic portfolio reallocation away from VOR BIOPHARMA INC.

Future Outlook

NA

Industry Context

This filing details a significant reduction in ownership by a major investor in a biopharma company. While the specific motivations for the sales are not disclosed, such divestment by a prominent entity like Reprogrammed Interchange LLC (associated with Reid Hoffman) can be interpreted by the market as a strategic portfolio adjustment or a response to specific company or market conditions within the biotechnology sector. It does not provide broader industry trends or specific competitive analysis.

Stakeholder Impact

• Shareholders: Existing shareholders may experience downward pressure on the stock price due to the significant selling by a major investor. The reduction in a large institutional stake could also reduce overall investor confidence in the company.
• Company Management: May face increased scrutiny and questions from the market regarding the reasons for the major shareholder's divestment and its potential implications for future capital raising or strategic partnerships.

Key Dates

Recommendation

The continuous and substantial selling by a major shareholder, Reprogrammed Interchange LLC and Reid Hoffman, reducing their stake to 18.6% and decreasing beneficial ownership by over one percent in recent days, signals a strong negative sentiment from a sophisticated investor. This divestment, especially after a reverse stock split, suggests a lack of conviction in the company's near-term prospects or a strategic exit. Such significant selling pressure typically leads to downward price movement and reduced investor confidence, warranting a 'sell' recommendation for existing holders and caution for potential buyers.

Keywords

VOR BIOPHARMA, Reprogrammed Interchange LLC, Reid Hoffman, Schedule 13D/A, share sales, beneficial ownership, stock split, biopharma, investor activity